OVID (Ovid Therapeutics) Inventories, Work In Process: $0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OVID Ovid Therapeutics Inc OVID
34 GF Score
Price $2.82
GF Value $0.99
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Ovid Therapeutics Inventories, Work In Process?

Ovid Therapeutics OVID +1.07% 34 Inventories, Work In Process is $0.00 Mil as of Jun. 2026. GuruFocus rates OVID with a GF Score™ of 34/100 and a GF Value™ of $0.99 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Work in process is the part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. Ovid Therapeutics's work in process for the quarter that ended in Jun. 2026 was $0.00 Mil.

Ovid Therapeutics Inventories, Work In Process Historical Data

* Premium members only.

The historical data trend for Ovid Therapeutics's Inventories, Work In Process can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ovid Therapeutics Inventories, Work In Process Chart

Ovid Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Work In Process
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Ovid Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Inventories, Work In Process Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
OVID
34GF Score
Ovid Therapeutics Inc OVID
Inventories, Work In Process is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ovid Therapeutics Inventories, Work In Process Calculation

That part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. This account contains the cost of the direct material, direct labor, and factory overhead placed into the products on the factory floor. A manufacturer must disclose in its financial statements the cost of its work-in-process as well as the cost of finished goods and materials on hand.

What does a Inventories, Work In Process of $0.00 Mil mean?
Ovid Therapeutics (OVID) has a Inventories, Work In Process of $0.00 Mil as of Jun. 2026. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Ovid Therapeutics and its competitors.
Is Ovid Therapeutics' Inventories, Work In Process too high?
Ovid Therapeutics' current Inventories, Work In Process is $0.00 Mil. Overall, Ovid Therapeutics has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ovid Therapeutics' Inventories, Work In Process compare to SGMT and CABA?
Ovid Therapeutics' Inventories, Work In Process of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Work In Process for a Biotechnology company?
A good Inventories, Work In Process depends on the Biotechnology industry context. However, Inventories, Work In Process should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Work In Process mean?
A high Inventories, Work In Process can signal that a stock is expensive relative to its fundamentals. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Ovid Therapeutics and its competitors. Ovid Therapeutics's current Inventories, Work In Process is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ovid Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Ovid Therapeutics (OVID) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.99, compared to a current price of $2.82 — trading 184.8% above its estimated fair value. The current Inventories, Work In Process is $0.00 Mil. Ovid Therapeutics' overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Work In Process calculated?
Inventories, Work In Process is calculated from a company's financial statements. For Ovid Therapeutics (OVID), the current Inventories, Work In Process is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ovid Therapeutics (OVID) Overvalued in 2026?

Based on GuruFocus' analysis, Ovid Therapeutics stock appears to be overvalued. The current stock price of $2.82 is trading 184.8% above its estimated GF Value™ of $0.99. GuruFocus considers Ovid Therapeutics to be Significantly Overvalued.

Key valuation signals for OVID:

  • Inventories, Work In Process: $0.00 Mil
  • GF Value™: $0.99 vs. price of $2.82 (184.8% above fair value)
  • GF Score™: 34/100 with 5 warning signs

No single metric tells the full story. See the OVID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ovid Therapeutics Business Description

Other Exchanges 1OT:Germany
Address 441 Ninth Avenue, 14th Floor, New York, NY, USA, 10001
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
34GF Score

Get the complete analysis for OVID

Inventories, Work In Process is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.82
Price
$0.99
GF Value